Navigation Links
Rigel Announces First Quarter 2013 Financial Results
Date:5/7/2013

0 million, which is expected to be sufficient to fund operations into 2015. 

"In the second quarter of 2013, we expect our partner AstraZeneca to report topline results from the two remaining Phase 3 studies of fostamatinib in rheumatoid arthritis, OSKIRA2 and OSKIRA3," said James M. Gower , chairman and chief executive officer of Rigel Pharmaceuticals. "Results from two other Phase 2 studies with R343 in allergic asthma and R333 in discoid lupus will follow later this year."

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis (RA) with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy, expected cash and investments and sufficiency of funds, the further development of, and the therapeutic and commercial potential of, fostamatinib, partnered with AstraZeneca, the potential uses and efficacy of Rigel's product candidates, the progress of Rigel's product d
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 NOT FOR RELEASE, ... INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO ... REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ) ... 30, 2014. "This was another very strong ... share above our original guidance and announced plans to merge ...
(Date:7/24/2014)...   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014.  The ... the Food and Drug Administration (FDA) had approved Zalviso.  ... notification to the company from the FDA regarding the ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... YORK, Sept. 8 ACCESS PHARMACEUTICALS, INC. (OTC ... in products for cancer, supportive care, today announced that the ... Conference in New York City on Tuesday, September 14th at ... floor of the New York Palace Hotel.   ...
... GE Healthcare announced today that results from its ... the September issue of Annals of Neurology . ... agent being developed by GE Healthcare, in the field ... the phase 2 study was to investigate the efficacy ...
Cached Medicine Technology:Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 2Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City 3Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology 2Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology 3
(Date:7/25/2014)... Parkulture is proud to announce that ... Jared “JJ” Woods, will be competing on NBC’s highest ... The show will premiere on local affiliates this coming ... the new Esquire Network on Tuesday, July 29th at ... balancing careers as a professional stuntman for film and ...
(Date:7/25/2014)... 25, 2014 Eye & Vision has ... their office location by expanding a new specialized ocular ... comprehensive visual electro-physiology clinic. , By acquiring specialized Visual ... experience in vision problems, patients with vision loss in ... advantage of the implementation of this specialized vision testing ...
(Date:7/25/2014)... 25, 2014 The report “Canada ... provides company shares and distribution shares data for ... profiles of the key market participants, pipeline products, ... market wherever available. , The data in the ... Rsearcher uses epidemiology and capital equipment-based models to ...
(Date:7/25/2014)... NH, 7/25/14) Researchers at Dartmouth-Hitchcock Norris Cotton Cancer ... system so it recognizes and attacks invading cancer cells. ... accepting everything as normal, even while cancer cells ... discussed in a review article published this week in ... jumpstart the body,s ability to fight tumors. Nanoparticles ...
(Date:7/25/2014)... 2014 The American Brain Tumor Association ... Development Trainer of Distinguished Events, and Corporate and Special ... Cancer Society, will be joining the ABTA in the ... will oversee the roll out of a nationwide brain ... The recently launched volunteer network will provide the Chicago-based ...
Breaking Medicine News(10 mins):Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2Health News:American Brain Tumor Association Recruits Director to Lead New Volunteer Network 2
... ... most wanted gifts for UK mums this Mother,s Day , ... London, UK (PRWEB) March 4, 2010 -- Voucher codes website Savoo.co.uk ... Boots voucher codes travel and clothing are the top three most desired gifts by ...
... ... Kidney Diseases recommends capsaicin as an effective skin care regimen to help relieve itching associated ... be extremely hot. Now there,s a new skin spray made with the essence of hot ... ...
... ... Weight Loss program. With documented success in other parts of the country, doctors Dan Buchanan ... to Cincinnati. , ... (PRWEB) March 4, 2010 -- UniqueU Medical Weight Loss Program opened in Kenwood, a ...
... ASTHMA HAVE INCREASED HEALTH RISKS , Pregnant women with ... symptoms and fetal growth abnormalities. Researchers from the Medical ... asthma to determine the effect of active and passive ... the women, 418 (18 percent) reported active smoking; among ...
... say they "had sex," what transpired is anyone,s guess. A ... that no uniform consensus existed when a representative sample of ... them. Is oral sex considered sex? It wasn,t ... anal sex? For around 20 percent of the participants, no. ...
... ... ... ... ...
Cached Medicine News:Health News:Voucher Site Savoo.co.uk Reveals What Mum's Really Want This Mother's Day 2Health News:Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus 2Health News:UniqueU Medical Weight Loss Program Opens Cincinnati Location 2Health News:News briefs from the March issue of Chest 2Health News:IU study finds no consensus in definitions of 'had sex' 2Health News:IU study finds no consensus in definitions of 'had sex' 3Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 2Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 3Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 4Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 5Health News:UMDNJ Online Graduate Certificate in Aging Program Accepting Applications 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: